Health
Shingrix Shingles Vaccine Associated With a 9 Percent Drop in Heart Risks
A study published in Nature Medicine on August 26, 2026, utilized a rapid U.S. vaccine transition to reveal that the recombinant shingles vaccine Shingrix is linked to a 9 percent reduction in cardiovascular burden over seven years among adults over 60. While not yet definitive proof, this builds on previous findings connecting the vaccine to lower dementia risk and sets the stage for ongoing randomized trials.